It positively influences the early stages of osteogenic differentiation, but in the later phases the RUNX2 expression is downregulated.10, 11, 12, 13 RUNX2 is known to be aberrantly expressed in metastatic prostate cancer cells,14 and is also known for promoting osteolytic lesions in breast cancer at metastasis.15 This evidence concerns the gene RUNX2 and prostate carcinoma.